Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

Shyam C. Panchal, William G. Ondo

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Purpose of Review: We discuss features of Parkinson’s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings: Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary: PDP is a morbid complication of Parkinson’s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.

Original languageEnglish (US)
Article number3
JournalCurrent Psychiatry Reports
Issue number1
StatePublished - Jan 1 2018


  • Antipsychotic
  • Delusions
  • Hallucinations
  • Parkinson’s disease
  • Pimavanserin
  • Psychosis

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis'. Together they form a unique fingerprint.

Cite this